Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections

BACKGROUND: Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant mutants is high, the biological cost associated with muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Rojas, Alexandro, Maciá, María D., Couce, Alejandro, Gómez, Cristina, Castañeda-García, Alfredo, Oliver, Antonio, Blázquez, Jesús
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855370/
https://www.ncbi.nlm.nih.gov/pubmed/20419114
http://dx.doi.org/10.1371/journal.pone.0010193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855370/
https://www.ncbi.nlm.nih.gov/pubmed/20419114
http://dx.doi.org/10.1371/journal.pone.0010193

Ejemplares similares